Group 1 - The company, Lee's Pharmaceutical Holdings Limited, announced an asset purchase agreement to acquire assets related to Alexza Pharmaceuticals for a total consideration of $15 million [1] - The acquired assets include all properties, equipment, materials (including work-in-progress), patents, intellectual property, technical know-how, rights, and assigned contracts associated with Alexza's business [1] Group 2 - The acquisition aligns with the company's strategy to expand its innovative drug delivery technology portfolio through the Staccato platform, which covers a wide range of indications [2] - The assets will complement the company's existing product pipeline and create synergies, enhancing value for the company and its shareholders [2] - The agreement with UCB, a leading biopharmaceutical company in the global epilepsy treatment field, marks a significant milestone in the company's global expansion strategy [2]
李氏大药厂(00950)：附属拟1500万美元收购Alexza Pharmaceuticals, Inc.与Alexza业务有关的所购资产